0001062993-24-010536.txt : 20240516 0001062993-24-010536.hdr.sgml : 20240516 20240516192035 ACCESSION NUMBER: 0001062993-24-010536 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240514 FILED AS OF DATE: 20240516 DATE AS OF CHANGE: 20240516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOHLIN GAREN G CENTRAL INDEX KEY: 0001254705 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 24957326 MAIL ADDRESS: STREET 1: C/O PRAECIS PHARMACEUTICALS INC STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-05-14 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001254705 BOHLIN GAREN G C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE STOUGHTON MA 02072 1 0 0 0 0 Common Stock 2024-05-14 4 M 0 28985 5.73 A 73760 D Common Stock 2024-05-14 4 S 0 28985 32.3033 D 44775 D Common Stock 2024-05-16 4 A 0 7693 0.00 A 52468 D Stock Option (Right to Purchase) 5.73 2024-05-14 4 M 0 28985 0 D 2025-03-19 Common Stock 28985 0 D The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. The option is fully vested and exercisable. /s/ Shirley R. Kuhlmann as Attorney-in-Fact for Garen G. Bohlin 2024-05-16